ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.66 USD 1.14% Market Closed
Market Cap: 281.7m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note

ProQR Therapeutics NV
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ProQR Therapeutics NV
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
ProQR Therapeutics NV
NASDAQ:PRQR
Current Portion of Long-Term Debt
€5.9m
CAGR 3-Years
23%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Current Portion of Long-Term Debt
$7.2m
CAGR 3-Years
23%
CAGR 5-Years
-28%
CAGR 10-Years
31%
Uniqure NV
NASDAQ:QURE
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Current Portion of Long-Term Debt
$5.9m
CAGR 3-Years
19%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Current Portion of Long-Term Debt
$440k
CAGR 3-Years
30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ProQR Therapeutics NV
Glance View

Market Cap
281.7m USD
Industry
Biotechnology

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

PRQR Intrinsic Value
2.72 USD
Undervaluation 2%
Intrinsic Value
Price

See Also

What is ProQR Therapeutics NV's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
5.9m EUR

Based on the financial report for Sep 30, 2024, ProQR Therapeutics NV's Current Portion of Long-Term Debt amounts to 5.9m EUR.

What is ProQR Therapeutics NV's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
37%

Over the last year, the Current Portion of Long-Term Debt growth was 55%. The average annual Current Portion of Long-Term Debt growth rates for ProQR Therapeutics NV have been 23% over the past three years , 37% over the past five years .

Back to Top